Sanofi (Sanofi) Equity-to-Asset

: 0.58 (As of Jun. 2023)

View and export this data going back to 2002. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sanofi's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $78,688 Mil. Sanofi's Total Assets for the quarter that ended in Jun. 2023 was $135,810 Mil. Therefore, Sanofi's Equity to Asset Ratio for the quarter that ended in Jun. 2023 was 0.58.

The historical rank and industry rank for Sanofi's Equity-to-Asset or its related term are showing as below:

SNY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.52 Med: 0.57 Max: 0.59
Current: 0.59

During the past 13 years, the highest Equity to Asset Ratio of Sanofi was 0.59. The lowest was 0.52. And the median was 0.57.

SNY's Equity-to-Asset is ranked better than
50.87% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs SNY: 0.59

Sanofi Equity-to-Asset Historical Data

The historical data trend for Sanofi's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

0.52

0.57

0.59

Sanofi Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset																0.57	0.58	0.59	0.58	0.59

Competitive Comparison

For the Drug Manufacturers - General subindustry, Sanofi's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi Equity-to-Asset Distribution

For the Drug Manufacturers industry and Healthcare sector, Sanofi's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Sanofi's Equity-to-Asset falls into.

Sanofi Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Sanofi's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	80741.549	/	137910.578
	=	0.59

Sanofi's Equity to Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

Equity to Asset (Q: Jun. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	78687.974	/	135810.401
	=	0.58

Sanofi (NAS:SNY) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Sanofi Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Sanofi's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi (Sanofi) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:Mexico SANF:Italy 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SNW2:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SANO:Austria

Address

46, avenue de la Grande Armée, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.